ADVERTISEMENT
ADVERTISEMENT
As China accelerates in biotech, U.S. confronts a new competitive reality
China’s advantage, executives said, lies not only in scale but in execution. Companies can move faster through early-stage trials, often at lower cost, and reach proof of concept more quickly than in the United States.
-
1759953093.png)
Staff Reporter - Thu, 30, Apr 2026
- 16:18 EDT
- 10
Speakers of the 'The State of BioPharma: Bold Bets, Big Shifts, and What Lies Ahead.' / USAIC
The global balance of power in pharmaceutical innovation is shifting, and not gradually. Executives and scientists gathered in Boston this week described a landscape in which China’s rapid advances in biotechnology — paired with India’s growing capabilities — are forcing the United States to rethink how it develops and delivers new medicines.
At a summit hosted by the USA–India Chamber of Commerce in Boston, industry leaders spoke with unusual candor about a transformation underway in research funding, clinical trials and the geography of innovation. The shift, they said, is not theoretical. It is already influencing where companies invest, where they run trials and how quickly they can bring drugs to market.
This post is for paying subscribers only
SUBSCRIBE NOW
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login